Market News / Story
Valion Bio Raises $50,000 in Private Sale of Series B Preferred and Warrants to 3i
·
Valion Bio entered into a letter agreement under its Series B Preferred Purchase Agreement to raise additional capital. On October 7, 2026, 3i agreed to purchase 50 Series B Non-Voting Convertible Preferred Shares and warrants to buy 1,539 common shares at an initial exercise price of $2.5520 per share, for total proceeds of $50,000. The private placement, conducted under Section 4(a)(2) and/or Rule 506(b), is subject to 3i’s satisfaction or waiver of closing…